Dr. Marcus Hanfling, DO

Dr. Hanfling practices at Cardiovascular Associates of the Delaware Valley,P A in Neptune, New Jersey.

Dr. Hanfling's NPI, 1922015007, was assigned on August 2, 2006. Dr. Hanfling graduated from NYIT College Of Osteopathic Medicine in 1981. Dr. Hanfling holds New Jersey license MB41000.

Dr. Hanfling's primary practice is Cardiovascular Associates of the Delaware Valley,P A, at 1 Hwy 35, Neptune, NJ 07753 in Monmouth County. The practice phone is (856) 547-0539.

Dr. Hanfling's primary practice is Cardiovascular Associates of the Delaware Valley,P A in Neptune, New Jersey. Dr. Hanfling is also affiliated with Riverview Medical Center. The medical group on file is Cardiovascular Associates of The Delaware Valley (The Heart House). Dmand AI also links Dr. Hanfling to 1 more hospital, 3 medical groups, 2 group practices and clinics and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hanfling practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Hanfling's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Hanfling is licensed in New Jersey.

CMS data shows 2,330 Medicare services from Dr. Hanfling across 16 procedure codes in 2024, for 385 Medicare patients. Medicare paid $227,035 for them. Every service was in an office.

CMS counts 385 Medicare patients who saw Dr. Hanfling in 2024. The largest group is 65 to 74, with 164 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.31, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Hanfling's median patient age at 74, with 47% women.

In 2024, Dr. Hanfling wrote 4,639 Medicare Part D claims for 612 patients. 85% of them were for generic drugs. CMS names the drug for 4,412 of them, across 52 drugs with 11 or more claims each, at $780,023 in total drug cost. In 2023, CMS named 4,088 claims across 53 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Hanfling for performance year 2024, reported as part of a group. Dr. Hanfling accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 362 general payments to Dr. Hanfling from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,530.

Dr. Hanfling graduated from NYIT College Of Osteopathic Medicine in 1981.